Summary by Moomoo AI
CRISPR Therapeutics AG's CEO, Samarth Kulkarni, engaged in a series of stock transactions from March 10 to March 12, 2024. Kulkarni acquired a total of 28,250 common shares through the exercise of derivative securities. Concurrently, he sold 14,385 shares in open market transactions. The sales occurred on March 11 and March 12, with prices ranging from $74.44 to $78.26 per share, resulting in a total market value of $1,108,263.04. Following these transactions, Kulkarni directly holds 208,122 shares of CRISPR Therapeutics. Additionally, he has an indirect beneficial ownership of 200,000 shares through The Kulkarni 2023 GRAT. The transactions are reported as in progress.